Clinical Trials Logo

Clinical Trial Summary

The correlation of coronary microvascular function and body composition with cardiopulmonary exercise capacity will be assessed in patients with heart failure with preserved ejection fraction.


Clinical Trial Description

We will select the patients with chest pain or ischemic symptoms with non-obstructive coronary artery disease (<50% stenosis) in coronary angiography and preserved ejection fraction (≥50%) in echocardiography. All patients will undergo body composition analysis and adenosine stress echocardiography with the evaluation of coronary artery blood flow by Doppler echocardiography and maximal oxygen consumption (VO2 max) by cardiopulmonary exercise test (CPET). Left ventricular end-diastolic pressure will be assessed during coronary angiography. Coronary flow reserve (CFR) is defined as the ratio of peak to baseline mean diastolic velocity of coronary blood flow. The correlation of CFR and body composition with cardiopulmonary exercise capacity will be assessed. ;


Study Design


Related Conditions & MeSH terms

  • Heart Failure
  • Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT number NCT04822649
Study type Interventional
Source Korea University Anam Hospital
Contact So Ree Kim, MD
Phone 821094534810
Email soree8826kim@gmail.com
Status Recruiting
Phase N/A
Start date April 15, 2021
Completion date December 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2
Recruiting NCT05441839 - UK Heart Failure With Preserved Ejection Fraction
Completed NCT01989299 - Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction
Terminated NCT03909295 - An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan. Phase 3
Completed NCT04327024 - Study of Verinurad in Heart Failure With Preserved Ejection Fraction Phase 2
Active, not recruiting NCT05136820 - Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study N/A
Completed NCT03988634 - Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF) Phase 3
Recruiting NCT03876223 - Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
Completed NCT04232345 - A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers Phase 1
Recruiting NCT05792059 - DevElopMent of Clinical PATHwaYs to the Diagnosis of Heart Failure With Preserved Ejection Fraction
Completed NCT03843060 - A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers Phase 1
Completed NCT01714752 - Evaluation of Left Ventricular Filling Pressures During Exercise N/A
Completed NCT06036186 - Study for the Treatment of Heart Failure With Preserved Ejection Fraction Associated With High Blood Pressure Using Right Atrial Pacing Controlled by the PressurePaceTM System N/A
Recruiting NCT05383287 - Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction (TRAITS-HFpEF)
Completed NCT03877224 - DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction Phase 3
Active, not recruiting NCT04847557 - A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial Phase 3